NexenBio is showing strong performance. This is interpreted as highlighting cooperation related to diabetes treatments following Novo Nordisk's expansion news.
As of 10:53 AM on the 14th, NexenBio is trading at 5,250 KRW, up 10.53% compared to the previous day.
According to foreign media reports the day before, Danish pharmaceutical company Novo Nordisk announced on the 10th (local time) plans to invest more than 42 billion kroner (approximately 4.9992 trillion KRW) to expand its existing manufacturing facility located in Kalundborg, Denmark.
This is due to the sharp increase in demand for the diabetes drug 'Ozempic' and the obesity drug 'Wegovy.' Most of the investment will be directed toward facilities producing active pharmaceutical ingredients (API) for semaglutide-based injectable drugs Ozempic and Wegovy, as well as the oral drug Rybelsus.
Recently, Novo Nordisk's Wegovy has been shown to reduce the risk of cardiovascular disease death by 18% and lower the risk of heart attack by 28% when taken.
Currently, Novo Nordisk has rapidly grown to become the largest company by market capitalization among European firms, significantly influencing the Danish economy. The issue lies in supply, as the supply cannot keep up with the rapidly increasing demand for major diabetes and obesity treatments.
Meanwhile, NexenBio announced that its subsidiary, RossBivo Therapeutics, signed a Confidential Disclosure Agreement (CDA) with Novo Nordisk for the joint development and technology export of diabetes treatments. Additionally, it has signed a Material Transfer Agreement (MTA) with Eli Lilly for the commercial development of diabetes and obesity treatments.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
